1. Protocol for assessing and visualizing cell microaggregate formation in whole blood by imaging flow cytometry; Jan 25, 2025; pubmed:39862430. View Protocol for assessing and visualizing cell microaggregate formation in whole blood by imaging flow cytometry on PubMed
  2. Flow Cytometry and Platelets; Aug 1, 2024; pubmed:39089755. View Flow Cytometry and Platelets on PubMed
  3. Dysregulation of platelet serotonin, 14-3-3, and GPIX in sudden infant death syndrome; May 15, 2024; pubmed:38750089. View Dysregulation of platelet serotonin, 14-3-3, and GPIX in sudden infant death syndrome on PubMed
  4. Platelet Physiology; Apr 23, 2024; pubmed:38653463. View Platelet Physiology on PubMed
  5. OMIP-097: High-parameter phenotyping of human platelets by spectral flow cytometry; Oct 3, 2023; pubmed:37786346. View OMIP-097: High-parameter phenotyping of human platelets by spectral flow cytometry on PubMed
  6. Clinical Cytometry for Platelets and Platelet Disorders; Jul 22, 2023; pubmed:37481322. View Clinical Cytometry for Platelets and Platelet Disorders on PubMed
  7. Platelet Phenotyping by Full Spectrum Flow Cytometry; Feb 13, 2023; pubmed:36779850. View Platelet Phenotyping by Full Spectrum Flow Cytometry on PubMed
  8. Expert opinion on the use of platelet secretion assay for the diagnosis of inherited platelet function disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology; Jun 30, 2022; pubmed:35770723. View Expert opinion on the use of platelet secretion assay for the diagnosis of inherited platelet function disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology on PubMed
  9. Comprehensive phenotyping of human platelets by single-cell cytometry; Jan 8, 2022; pubmed:34997669. View Comprehensive phenotyping of human platelets by single-cell cytometry on PubMed
  10. Inhibition of transcription factor NFAT activity in activated platelets enhances their aggregation and exacerbates gram-negative bacterial septicemia; Jan 7, 2022; pubmed:34995475. View Inhibition of transcription factor NFAT activity in activated platelets enhances their aggregation and exacerbates gram-negative bacterial septicemia on PubMed
  11. Sex-specific platelet activation through protease-activated receptor-1 in patients undergoing cardiac catheterization; Nov 22, 2021; pubmed:34808540. View Sex-specific platelet activation through protease-activated receptor-1 in patients undergoing cardiac catheterization on PubMed
  12. Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology; Sep 28, 2021; pubmed:34580997. View Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology on PubMed
  13. Platelet Activation and Reactivity in a Large Cohort of Patients with Gaucher Disease; Sep 10, 2021; pubmed:34507369. View Platelet Activation and Reactivity in a Large Cohort of Patients with Gaucher Disease on PubMed
  14. Immunophenotypic Analysis of Platelets by Flow Cytometry; Jun 25, 2021; pubmed:34170638. View Immunophenotypic Analysis of Platelets by Flow Cytometry on PubMed
  15. Platelet count and disease - editorial policy; May 10, 2021; pubmed:33969797. View Platelet count and disease - editorial policy on PubMed
  16. Platelet Immunophenotyping by High-Dimensional Mass Cytometry; May 5, 2021; pubmed:33950581. View Platelet Immunophenotyping by High-Dimensional Mass Cytometry on PubMed
  17. Activation of platelet-rich plasma by pulse electric fields: Voltage, pulse width and calcium concentration can be used to control and tune the release of growth factors, serotonin and hemoglobin; Apr 23, 2021; pubmed:33891598. View Activation of platelet-rich plasma by pulse electric fields: Voltage, pulse width and calcium concentration can be used to control and tune the release of growth factors, serotonin and hemoglobin on PubMed
  18. Platelet mass cytometry: Optimization of sample, reagent, and analysis parameters; Jan 5, 2021; pubmed:33399275. View Platelet mass cytometry: Optimization of sample, reagent, and analysis parameters on PubMed
  19. Decreased platelet surface phosphatidylserine predicts increased bleeding in patients with severe factor VIII deficiency; Dec 28, 2020; pubmed:33370471. View Decreased platelet surface phosphatidylserine predicts increased bleeding in patients with severe factor VIII deficiency on PubMed
  20. Biomarkers of platelet activation and cardiovascular risk in the DAPT trial; Jul 20, 2020; pubmed:32683645. View Biomarkers of platelet activation and cardiovascular risk in the DAPT trial on PubMed
  21. An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension; Dec 21, 2019; pubmed:31858186. View An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension on PubMed
  22. Platelet surface marker analysis by mass cytometry; Sep 24, 2019; pubmed:31544564. View Platelet surface marker analysis by mass cytometry on PubMed
  23. Using extracellular calcium concentration and electric pulse conditions to tune platelet-rich plasma growth factor release and clotting; Mar 24, 2019; pubmed:30902134. View Using extracellular calcium concentration and electric pulse conditions to tune platelet-rich plasma growth factor release and clotting on PubMed
  24. Publisher Correction: GLS-409, an Antagonist of Both P2Y<sub>1</sub> and P2Y<sub>12</sub>, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation; Dec 1, 2018; pubmed:30498241. View Publisher Correction: GLS-409, an Antagonist of Both P2Y<sub>1</sub> and P2Y<sub>12</sub>, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation on PubMed
  25. Laboratory monitoring of P2Y<sub>12</sub> inhibitors: communication from the SSC of the ISTH; Oct 5, 2018; pubmed:30284374. View Laboratory monitoring of P2Y<sub>12</sub> inhibitors: communication from the SSC of the ISTH on PubMed
  26. GLS-409, an Antagonist of Both P2Y<sub>1</sub> and P2Y<sub>12</sub>, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation; Sep 30, 2018; pubmed:30266987. View GLS-409, an Antagonist of Both P2Y<sub>1</sub> and P2Y<sub>12</sub>, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation on PubMed
  27. Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease; Sep 29, 2018; pubmed:30264918. View Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease on PubMed
  28. Tunable activation of therapeutic platelet-rich plasma by pulse electric field: Differential effects on clot formation, growth factor release, and platelet morphology; Sep 27, 2018; pubmed:30256831. View Tunable activation of therapeutic platelet-rich plasma by pulse electric field: Differential effects on clot formation, growth factor release, and platelet morphology on PubMed
  29. Mass Cytometry Reveals Distinct Platelet Subtypes in Healthy Subjects and Novel Alterations in Surface Glycoproteins in Glanzmann Thrombasthenia; Jul 10, 2018; pubmed:29985398. View Mass Cytometry Reveals Distinct Platelet Subtypes in Healthy Subjects and Novel Alterations in Surface Glycoproteins in Glanzmann Thrombasthenia on PubMed
  30. Using flow cytometry to monitor glycoprotein IIb-IIIa activation; May 26, 2018; pubmed:29799301. View Using flow cytometry to monitor glycoprotein IIb-IIIa activation on PubMed
  31. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor: reply; Jan 10, 2018; pubmed:29314666. View Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor: reply on PubMed
  32. Platelet Function in ITP, Independent of Platelet Count, Is Consistent Over Time and Is Associated with Both Current and Subsequent Bleeding Severity; Jan 6, 2018; pubmed:29304534. View Platelet Function in ITP, Independent of Platelet Count, Is Consistent Over Time and Is Associated with Both Current and Subsequent Bleeding Severity on PubMed
  33. Calpain-1 regulates platelet function in a humanized mouse model of sickle cell disease; Nov 5, 2017; pubmed:29101791. View Calpain-1 regulates platelet function in a humanized mouse model of sickle cell disease on PubMed
  34. High serum serotonin in sudden infant death syndrome; Jul 5, 2017; pubmed:28674018. View High serum serotonin in sudden infant death syndrome on PubMed
  35. Reply: Collapse of the Aspirin Empire: Is it Diabetic Gastroparesis or Cardioprotective Paresis?; Jun 10, 2017; pubmed:28595709. View Reply: Collapse of the Aspirin Empire: Is it Diabetic Gastroparesis or Cardioprotective Paresis? on PubMed
  36. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor; Jan 17, 2017; pubmed:28092426. View Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor on PubMed
  37. Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus; Jan 17, 2017; pubmed:28089180. View Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus on PubMed
  38. Whole Blood Analysis of Leukocyte-Platelet Aggregates; Oct 11, 2016; pubmed:27723089. View Whole Blood Analysis of Leukocyte-Platelet Aggregates on PubMed
  39. Modification of Pulsed Electric Field Conditions Results in Distinct Activation Profiles of Platelet-Rich Plasma; Aug 25, 2016; pubmed:27556645. View Modification of Pulsed Electric Field Conditions Results in Distinct Activation Profiles of Platelet-Rich Plasma on PubMed
  40. Assessment of whole blood thrombosis in a microfluidic device lined by fixed human endothelium; Jul 29, 2016; pubmed:27464497. View Assessment of whole blood thrombosis in a microfluidic device lined by fixed human endothelium on PubMed
  41. Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial; Mar 25, 2016; pubmed:27009617. View Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial on PubMed
  42. Platelet Physiology; Mar 2, 2016; pubmed:26926581. View Platelet Physiology on PubMed
  43. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis; Jan 9, 2016; pubmed:26743169. View Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis on PubMed
  44. New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors; Nov 21, 2015; pubmed:26588064. View New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors on PubMed
  45. In Vivo and protease-activated receptor-1-mediated platelet activation in patients presenting for cardiac catheterization; Nov 12, 2015; pubmed:26556638. View In Vivo and protease-activated receptor-1-mediated platelet activation in patients presenting for cardiac catheterization on PubMed
  46. Aspirin response: Differences in serum thromboxane B2 levels between clinical studies; Aug 14, 2015; pubmed:26270593. View Aspirin response: Differences in serum thromboxane B2 levels between clinical studies on PubMed
  47. Soluble CD40 Ligand in Aspirin-Treated Patients Undergoing Cardiac Catheterization; Aug 4, 2015; pubmed:26237513. View Soluble CD40 Ligand in Aspirin-Treated Patients Undergoing Cardiac Catheterization on PubMed
  48. Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia; Jul 31, 2015; pubmed:26224646. View Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia on PubMed
  49. Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP; Jul 4, 2015; pubmed:26138687. View Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP on PubMed
  50. Platelet-rich plasma stimulated by pulse electric fields: Platelet activation, procoagulant markers, growth factor release and cell proliferation; Jun 2, 2015; pubmed:26030682. View Platelet-rich plasma stimulated by pulse electric fields: Platelet activation, procoagulant markers, growth factor release and cell proliferation on PubMed
  51. A review of platelet secretion assays for the diagnosis of inherited platelet secretion disorders; Apr 17, 2015; pubmed:25879272. View A review of platelet secretion assays for the diagnosis of inherited platelet secretion disorders on PubMed
  52. Platelet activation using electric pulse stimulation: growth factor profile and clinical implications; Aug 28, 2014; pubmed:25159369. View Platelet activation using electric pulse stimulation: growth factor profile and clinical implications on PubMed
  53. The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease; Aug 21, 2014; pubmed:25140584. View The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease on PubMed
  54. Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial; Jul 26, 2014; pubmed:25060370. View Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial on PubMed
  55. Do immature platelet levels in chest pain patients presenting to the emergency department aid in the diagnosis of acute coronary syndrome?; May 9, 2014; pubmed:24806286. View Do immature platelet levels in chest pain patients presenting to the emergency department aid in the diagnosis of acute coronary syndrome? on PubMed
  56. Antiplatelet activity, P2Y₁ and P2Y₁₂ inhibition, and metabolism in plasma of stereoisomers of diadenosine 5',5'″-P¹ ,P⁴-dithio-P²,P³-chloromethylenetetraphosphate; Apr 12, 2014; pubmed:24722456. View Antiplatelet activity, P2Y₁ and P2Y₁₂ inhibition, and metabolism in plasma of stereoisomers of diadenosine 5',5'″-P¹ ,P⁴-dithio-P²,P³-chloromethylenetetraphosphate on PubMed
  57. A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation; Dec 26, 2013; pubmed:24368019. View A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation on PubMed
  58. P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity; May 17, 2013; pubmed:23676293. View P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity on PubMed
  59. Platelet activation and inhibition in sickle cell disease (pains) study; Mar 9, 2013; pubmed:23469943. View Platelet activation and inhibition in sickle cell disease (pains) study on PubMed
  60. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function; Jan 22, 2013; pubmed:23333143. View Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function on PubMed
  61. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study; Dec 11, 2012; pubmed:23223867. View Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study on PubMed
  62. A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity; Nov 23, 2012; pubmed:23171128. View A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity on PubMed
  63. Modified diadenosine tetraphosphates with dual specificity for P2Y1 and P2Y12 are potent antagonists of ADP-induced platelet activation; Oct 23, 2012; pubmed:23083103. View Modified diadenosine tetraphosphates with dual specificity for P2Y1 and P2Y12 are potent antagonists of ADP-induced platelet activation on PubMed
  64. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers; Apr 3, 2012; pubmed:22464259. View A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers on PubMed
  65. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease; Nov 18, 2011; pubmed:22088980. View Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease on PubMed
  66. The human endogenous circadian system causes greatest platelet activation during the biological morning independent of behaviors; Sep 21, 2011; pubmed:21931750. View The human endogenous circadian system causes greatest platelet activation during the biological morning independent of behaviors on PubMed
  67. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44; Jun 30, 2011; pubmed:21713327. View Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44 on PubMed
  68. Effects of in vitro adult platelet transfusions on neonatal hemostasis; Feb 16, 2011; pubmed:21320282. View Effects of in vitro adult platelet transfusions on neonatal hemostasis on PubMed
  69. The Platelet Activity After Clopidogrel Termination (PACT) study; Aug 26, 2010; pubmed:20736449. View The Platelet Activity After Clopidogrel Termination (PACT) study on PubMed
  70. Platelet reactivity with prolonged aspirin treatment--steady going at 2 year; May 18, 2010; pubmed:20472961. View Platelet reactivity with prolonged aspirin treatment--steady going at 2 year on PubMed
  71. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization; Dec 10, 2009; pubmed:19996015. View Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization on PubMed
  72. Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors; Dec 1, 2009; pubmed:19945153. View Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors on PubMed
  73. Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis; Nov 20, 2009; pubmed:19922435. View Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis on PubMed
  74. Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity; Oct 27, 2009; pubmed:19852691. View Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity on PubMed
  75. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial; May 14, 2009; pubmed:19435740. View Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial on PubMed
  76. Whole blood analysis of leukocyte-platelet aggregates; Sep 5, 2008; pubmed:18770779. View Whole blood analysis of leukocyte-platelet aggregates on PubMed
  77. Immunophenotypic analysis of platelets; Sep 5, 2008; pubmed:18770767. View Immunophenotypic analysis of platelets on PubMed
  78. Effects of physiologic agonists on canine whole blood flow cytometry assays of leukocyte-platelet aggregation and platelet activation; Apr 15, 2008; pubmed:18405981. View Effects of physiologic agonists on canine whole blood flow cytometry assays of leukocyte-platelet aggregation and platelet activation on PubMed
  79. The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities; Nov 21, 2007; pubmed:18021304. View The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities on PubMed
  80. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin; Jun 29, 2007; pubmed:17598013. View The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin on PubMed
  81. Cystic fibrosis heterozygotes do not have increased platelet activation; May 29, 2007; pubmed:17532368. View Cystic fibrosis heterozygotes do not have increased platelet activation on PubMed
  82. Indices of platelet activation and the stability of coronary artery disease; Mar 21, 2007; pubmed:17371489. View Indices of platelet activation and the stability of coronary artery disease on PubMed
  83. Measuring antiplatelet drug effects in the laboratory; Jan 24, 2007; pubmed:17239428. View Measuring antiplatelet drug effects in the laboratory on PubMed
  84. Current options in platelet function testing; Nov 14, 2006; pubmed:17097417. View Current options in platelet function testing on PubMed
  85. Preconditioning ischemia attenuates molecular indices of platelet activation-aggregation; Sep 26, 2006; pubmed:16995902. View Preconditioning ischemia attenuates molecular indices of platelet activation-aggregation on PubMed
  86. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance; Jun 21, 2006; pubmed:16785341. View Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance on PubMed
  87. Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity; Oct 26, 2005; pubmed:16241954. View Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity on PubMed
  88. Clopidogrel linking evaluation of platelet response variability to mechanism of action; Aug 16, 2005; pubmed:16098429. View Clopidogrel linking evaluation of platelet response variability to mechanism of action on PubMed
  89. GPIIb/IIIa inhibitor-induced dethrombosis; Mar 4, 2005; pubmed:15744548. View GPIIb/IIIa inhibitor-induced dethrombosis on PubMed
  90. Platelet activation in cystic fibrosis; Feb 12, 2005; pubmed:15705796. View Platelet activation in cystic fibrosis on PubMed
  91. GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention; Jan 27, 2005; pubmed:15670038. View GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention on PubMed
  92. Application of flow cytometry to platelet disorders; Oct 22, 2004; pubmed:15497093. View Application of flow cytometry to platelet disorders on PubMed
  93. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization; Jun 15, 2004; pubmed:15193700. View Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization on PubMed
  94. Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation; Oct 30, 2003; pubmed:14583364. View Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation on PubMed
  95. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention; Feb 22, 2003; pubmed:12595861. View Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention on PubMed
  96. The cleaved peptide of PAR1 is a more potent stimulant of platelet-endothelial cell adhesion than is thrombin; Feb 4, 2003; pubmed:12563219. View The cleaved peptide of PAR1 is a more potent stimulant of platelet-endothelial cell adhesion than is thrombin on PubMed
  97. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab; Oct 31, 2001; pubmed:11685164. View Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab on PubMed
  98. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction; Oct 5, 2001; pubmed:11583872. View Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction on PubMed
  99. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation; Sep 19, 2001; pubmed:11560852. View Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation on PubMed
  100. Laser scanning cytometry: a novel method for the detection of platelet--endothelial cell adhesion; Mar 22, 2001; pubmed:11260598. View Laser scanning cytometry: a novel method for the detection of platelet--endothelial cell adhesion on PubMed